Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

President Joe Biden recently gave an update on his treatment for metastatic prostate cancer. A urologist explains ways to ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings ...

WASHINGTON — Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form of prostate cancer he was diagnosed with after leaving office, ...

Former President Joe Biden is now receiving radiation and hormone therapy as part of his ongoing treatment for prostate cancer, a spokesperson said Saturday. The nation’s 46th president was diagnosed ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as effectively as standard hormone injections in men with locally advanced or ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL ...

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...

July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its ...